Inclusion Criteria:

- Advanced (metastatic) RCC

- Histology: clear cell, papillary or chromophobe

- 3 out 6 risk factors (by MSKCC criteria and one additional criterion: multiple sites
of metastasis) or not candidates for or refuse sunitinib.

- Must have at least one measurable metastatic site according to RECIST criteria that
has not been previously irradiated.

- Must be deemed surgical candidates for cytoreductive nephrectomy by the urologist.

- Age 18 years of age or older

- EGOG PS 0-2

- Adequate bone marrow function

- Adequate liver function as shown by:

- Adequate renal function

- Fasting serum cholesterol AND fasting triglycerides within normal limits

- Signed informed consent

Exclusion Criteria:

- Collecting duct, medullary histologies or sarcomatoid differentiation.

- CNS or leptomeningeal metastases.

- Inappropriate candidates for cytoreductive nephrectomy or who have any severe and/or
uncontrolled medical conditions or other conditions that could affect their
participation in the study

- severely impaired lung function

- uncontrolled diabetes

- active (acute or chronic) or uncontrolled severe infections

- liver disease such as cirrhosis, chronic active hepatitis or chronic persistent
hepatitis

- Ineligible for cytoreductive nephrectomy

- Current or prior systemic anticancer therapies (including chemotherapy, antibody
based therapy, or investigational drugs)

- Other malignancies within the past 3 years except for localized carcinoma of the
cervix, basal or squamous cell carcinomas of the skin, or localized prostate cancer
with Gleason Score less than 7 treated with radiation or surgery and no evidence of
progression.

- Major surgery (defined as requiring general anesthesia) or significant traumatic
injury within 4 weeks of start of enrollment

- Anticipated major surgery (other than CN) during the course of the study

- A known history of HIV seropositivity

- Hepatitis C seropositivity

- Chronic, systemic treatment with corticosteroids or another immunosuppressive agent.
Topical or inhaled corticosteroids are allowed.

- Immunization with attenuated live vaccines within one week of study entry or during
study period

- Known hypersensitivity to RAD001 (everolimus) or other rapamycins or to its
excipients

- Impairment of gastrointestinal function or gastrointestinal disease

- Active, bleeding diathesis

- Female patients who are pregnant or breast feeding, or adults of reproductive
potential who are not using effective birth control methods.

- History of noncompliance to medical regimens

- Unwilling to or unable to comply with the protocol including mandated biopsies